Vaccine Info

MMR II Rubella Vaccine


M-M-R II is also known as Measles, Mumps, and Rubella Virus Vaccine Live, is a live virus vaccine, containing weakened forms of measles virus, mumps virus, and rubella virus.


It is indicated for simultaneous vaccination against measles (rubeola), mumps, and rubella (German measles).

This vaccine is usually given to people one-year-old or older.


M-M-R II is given as a shot administered subcutaneously, preferably into the outer aspect of the arm. The dose of the vaccine is the same for everyone.

If your child gets the shot when he or she is one year old or older, a second dose is recommended.

Often, the second dose is given right before the child goes to elementary school (4 to 6 years of age).

If your child is less than one year old when he or she first gets the shot, a second dose should be given when they are 12 to 15 months old.

Then, a third shot should be given between 4 and 6 years of age.

Your doctor will decide the best time and number of shots by using official recommendations.

M-M-R II works by helping the immune system protect you or your child from getting measles, mumps, or rubella.

Clinical Trial NCT01702428: Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

This study will evaluate the consistency of the immune response to three different lots of GSK Biologicals' trivalent investigational MMR vaccine (NV_MMR) and compare its immunogenicity to the US standard of care comparator vaccine M-M-R II, Merck and Co., Inc. (COM_MMR) in children during their second year of life.

The INV_MMR vaccine will be given as one of three consistency lots manufactured to target potencies designated as INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3.

The COM_MMR vaccine will be given as one of two lots designated COM_MMR_L1 and COM_MMR_L2 and will be analysed as pooled lots within the study.

The MMR vaccine will be co-administered with Varivax (VV), Havrix (HAV) and (in the US sub-cohort only) Prevnar 13 (PCV-13) which are routinely administered to children of this age in the US.

09/30/2019 - 16:30